Trial Profile
A study analyzing genomic characteristics of nivolumab/ipilimumab with or without CBM-588 supplementation in patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs Clostridium butyricum M588 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 20 May 2022 New trial record
- 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research